Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

NCT ID: NCT02274779

Last Updated: 2025-08-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 68 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-08-20
• Study Completion Date: 2024-07-22

Brief Summary

There is an increasing number of reports describing the existence of a proportion of prostate cancer patients who present with a reduced number of metastases (<5 lesions) at relapse. This oligometastatic status has also been recognized in other tumor types such as melanoma, soft tissue sarcoma, liver, lung, and breast cancer, and has influenced the management of these malignancies in that a more radical treatment such as surgical resection has been employed. Positron Emission Tomography-Computed Tomography (PET-CT) studies with tracers such as choline or acetate are reliable tools to help with the diagnosis of oligometastatic disease after biochemical treatment failure in prostate cancer. An aggressive treatment combining androgen depriving therapy (ADT) and and high-dose irradiation to the oligometastatic lesions, as detected by PET-CT, may be proposed for these oligometastatic patients. Such a treatment strategy may hypothetically succeed to prolong the failure-free interval between two consecutive ADT courses, or even cure selected patients with limited metastatic burden. In this study the investigators plan to assess biochemical or clinical relapse-free survival at 2 years of prostate cancer with 1-5 oligometastases treated concomitantly with high-dose conformal Radiation Therapy and LH-RH agonists.

Detailed Description

1. Hormonotherapy

Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.

Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical.

2. Radiotherapy

Conformational Radiotherapy techniques in Intensity-Modulated (IMRT)

2.1) Doses prescribed

• PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy
• PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy
• PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.
• PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy.

2.2) Treatment

Radiation Guided by a picture (IGRT) will be performed daily. This daily recalibration will be based at least on bone structures. It will be possible to readjust the nodal structures.

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Hight dose IMRT, ELIGARD

• PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy
• PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy
• PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.
• PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy.

Group Type: EXPERIMENTAL

ELIGARD

Intervention Type: DRUG

Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.

Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical.

Interventions

ELIGARD

Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.

Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical.

Intervention Type: DRUG

Other Intervention Names

Leuproréline

Eligibility Criteria

Inclusion Criteria

1. Histologically proven adenocarcinoma of the prostate

2. Patients aged 18 years or more

3. PS 0-1

4. Previous radical treatment to the prostate (radiotherapy or surgery)

5. PSA increase of at least 3 assays in the same laboratory over the last 12 months.

6. 1-5 pelvic lymph node metastases detected with 18FCH-PET. A relapse in the dressing prostatectomy is associated possible.

7. Upper limit of lymph node metastases: aortic bifurcation

8. Respect dosimetric constraints to organs at risk

9. Treatment with hormone therapy may be started before inclusion, to a maximum of three months prior to Day 1 of radiotherapy. This hormone will necessarily be preceded by a free interval treatment of at least 6 months since the last injection, by adding the duration of action of this predictable injection (1, 3 or 6 months)

10. Patient affiliated to a social security scheme

11. Patient Information and written informed consent form signed

Exclusion Criteria

1. bone or visceral metastatic relapse associated

2. para-aortic nodal relapse (the upper limit is tolerated aortic bifurcation)

3. more than 5 lymph node metastases

4. Proof of metastases at initial diagnosis

5. Evidence of distant metastases in the pelvic lymph nodes or outside the prostate bed

6. prior pelvic lymph nodes Irradiation. Irradiation of the bed of the prostate is not an exclusion criterion, but the junction between prior irradiation bed prostatectomy and radiation field pelvic lymph nodes should be examined carefully

7. castration resistance defined by clinical or biochemical progression despite a combined androgen blockade

8. known contraindications to pelvic irradiation (eg, chronic inflammatory bowel disease, ...)

9. known contraindications to hormone therapy, according to standard recommendations in force

10. serious Hypertension not controlled by appropriate treatment

11. Other concomitant cancer or history of cancer (within 5 years prior to study entry), except basal cell or squamous cell carcinomas of the skin.

12. Patient with a psychological, familial, sociological or geographical potentially hampering compliance with the study protocol and follow-up schedule

13. Patient already included in another interventional study involving the approval of a CPP during his screening for the study OLIGOPELVIS

14. Private person of liberty or major trust

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Astellas Pharma Inc

INDUSTRY

Sponsor Role: collaborator

Institut Cancerologie de l'Ouest

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

SUPIOT Stéphane, MD

Role: PRINCIPAL_INVESTIGATOR

Institut de Cancérologie de l'Ouest (ICO) - Nantes, France

Locations

ICO Paul Papin

Angers, , France

ICO René Gauducheau

Saint-Herblain, , France

Countries

France

References

Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F. OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer. 2015 Sep 25;15:646. doi: 10.1186/s12885-015-1579-0.

Reference Type: DERIVED

PMID: 26408012 (View on PubMed)

Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, Renard-Penna R, Salin A, Lebret T, Villers A, Soulie M, de la Taille A, Flamand V. Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. J Urol. 2015 Oct;194(4):983-8. doi: 10.1016/j.juro.2015.04.103. Epub 2015 May 9.

Reference Type: DERIVED

PMID: 25963190 (View on PubMed)

Other Identifiers

ICO-N-2014-02

Identifier Type: -

Identifier Source: org_study_id